Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an update.
Botanix Pharmaceuticals has disclosed a change in director Vincent Ippolito’s interests following his participation in Tranche 2 of a share placement approved by shareholders on 1 April 2026. Ippolito, through The Ippolito Trust, acquired 1,666,667 fully paid ordinary shares at $0.06 per share, increasing the trust’s holding to 16,668,311 shares while retaining 16,000,000 performance rights expiring in December 2029.
The subscription occurred during a closed period but proceeded with prior written clearance from the board and shareholder approval. The additional director investment signals confidence in the company’s capital-raising efforts and supports Botanix’s balance sheet as it continues to execute its strategic and operational objectives in the pharmaceutical market.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is a biotechnology company focused on developing and commercialising dermatology and skin-health treatments. The company is listed on the ASX and raises capital through share placements to fund its development and commercial activities in the pharmaceutical sector.
Average Trading Volume: 15,652,456
Technical Sentiment Signal: Sell
Current Market Cap: A$94.92M
See more insights into BOT stock on TipRanks’ Stock Analysis page.